---
figid: PMC5579385__MOL2-11-1273-g008
figlink: /pmc/articles/PMC5579385/figure/mol212102-fig-0008/
number: F8
caption: MEK inhibitors suppress ERK‐mediated HER2 Thr701 phosphorylation to enhance
  clathrin‐dependent HER2/EGFR dimerization and subsequent Akt activation. ERK1/2
  activated by RTK/MEK signaling axis feedback phosphorylates HER2 and EGFR at Thr701
  and Thr669, respectively, in response to EGF stimulation. HER2 Thr701 phosphorylation
  negatively regulates the heterodimerization of EGFR and HER2 via reducing the clathrin‐binding
  activity of HER2, resulting in the clathrin‐mediated endocytosis of EGFR homodimer
  to attenuate EGF signaling. Suppression of ERK activity by MEK inhibitors relieves
  the negative regulation on the clathrin‐dependent heterodimerization of HER2 and
  EGFR by reducing HER2 Thr701 phosphorylation. The increased binding between EGFR
  and HER2 enhanced and prolonged the activation of these RTKs and the downstream
  PI3K/Akt pathway, and may thereby contribute to the drug resistance to MEK inhibitors.
pmcid: PMC5579385
papertitle: MEK inhibitors induce Akt activation and drug resistance by suppressing
  negative feedback ERK‐mediated HER2 phosphorylation at Thr701.
reftext: Chia‐Hung Chen, et al. Mol Oncol. 2017 Sep;11(9):1273-1287.
pmc_ranked_result_index: '3835'
pathway_score: 0.9725488
filename: MOL2-11-1273-g008.jpg
figtitle: MEK inhibitors suppress ERK‐mediated HER2 Thr701 phosphorylation to enhance
  clathrin‐dependent HER2/EGFR dimerization and subsequent Akt activation
year: '2017'
organisms: Homo sapiens
ndex: c26f460a-dec4-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5579385__MOL2-11-1273-g008.html
  '@type': Dataset
  description: MEK inhibitors suppress ERK‐mediated HER2 Thr701 phosphorylation to
    enhance clathrin‐dependent HER2/EGFR dimerization and subsequent Akt activation.
    ERK1/2 activated by RTK/MEK signaling axis feedback phosphorylates HER2 and EGFR
    at Thr701 and Thr669, respectively, in response to EGF stimulation. HER2 Thr701
    phosphorylation negatively regulates the heterodimerization of EGFR and HER2 via
    reducing the clathrin‐binding activity of HER2, resulting in the clathrin‐mediated
    endocytosis of EGFR homodimer to attenuate EGF signaling. Suppression of ERK activity
    by MEK inhibitors relieves the negative regulation on the clathrin‐dependent heterodimerization
    of HER2 and EGFR by reducing HER2 Thr701 phosphorylation. The increased binding
    between EGFR and HER2 enhanced and prolonged the activation of these RTKs and
    the downstream PI3K/Akt pathway, and may thereby contribute to the drug resistance
    to MEK inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CLTC
  - EGF
  - CLTB
  - PIK3R4
  - PIK3CA
  - EGFR
  - PIK3CB
  - PIK3CD
  - AKT2
  - CLTA
  - AKT3
  - PIK3CG
  - MAPK1
  - PIK3R3
  - MAPK3
  - AKT1
  - PIK3R5
  - ERBB2
  - MAP2K1
  - PIK3R6
  - tyrosine
genes:
- word: Clathrin
  symbol: Clathrin
  source: bioentities_symbol
  hgnc_symbol: CLTC
  entrez: '1213'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: Clathrin
  symbol: Clathrin
  source: bioentities_symbol
  hgnc_symbol: CLTB
  entrez: '1212'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Clathrin
  symbol: Clathrin
  source: bioentities_symbol
  hgnc_symbol: CLTA
  entrez: '1211'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: MEK1
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
chemicals:
- word: tyrosine
  source: MESH
  identifier: D014443
diseases: []
figid_alias: PMC5579385__F8
redirect_from: /figures/PMC5579385__F8
figtype: Figure
---
